Myeloproliferative Neoplasms | Topics

The FDA approved the first and only erythroid maturation agent for the treatment of anemia in patients with lower-risk myelodysplastic syndromes.

This study highlighted the need for novel therapies in myelofibrosis treatment, given that salvage therapies could potentially improve patient outcomes.

In this second part of our two-part review, we discuss the use of mutation profiling in the diagnosis, prognosis, and treatment of patients with myeloproliferative neoplasms and other myeloid diseases.